EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annu... (o develop and commercialize new compound...)

EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting

Date:4/22/2008

o develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

CONTACT:

Ginny Dunn

Associate Director, Corpo
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related biology technology :

1. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
2. EntreMed Receives Nasdaq Deficiency Notice
3. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
4. EntreMed Announces 2008 Corporate and Clinical Program Priorities
5. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
6. EntreMed to Present at BIO CEO and Investor Conference
7. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
8. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
9. EntreMed Appoints Senior Vice President of Research and Development
10. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
11. Glass Lewis & Co. Recommends Renovis Shareholders Vote For Merger With Evotec

Post Your Comments:

(Date:6/18/2013)... Clara, CA (PRWEB) June 18, 2013 ... to standard size SEMs but have limited performance and ... lower resolution. Full size SEMs would normally provide better ... more knowledge to operate and have a higher cost ... address the gap between these two types of ...

(Date:6/18/2013)... 17, 2013) A million electric cars could be on ... with the help of research by the United States Department ... Waterloo. , Professor Zhongwei Chen is part of a team ... non-precious materials to replace the expensive platinum catalysts in fuel ... of fuel cells in vehicles is the cost of the ...

(Date:6/18/2013)... -- China Cord Blood Corporation (NYSE: CO ... cord blood collection, laboratory testing, hematopoietic stem cell processing, ... unaudited financial results for the fourth quarter and full ... Fourth Quarter of Fiscal 2013 Highlights ... 2013 increased by 33.3% to RMB133.0 million ($21.4 million) ...

(Date:6/18/2013)... In support of Swiss contributions to ... of Switzerland in New York is pleased to welcome ... PlanetSolar , to Manhattan. PlanetSolar is in New ... tour with scientists on board from the University of ... exclusively on energy from the sun and eliminates the ...

[0] Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes [0] US and Canadian researchers drive towards cheaper fuel cells for electric cars [0] China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 [0] Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City

... Inc.,(NASDAQ: ISOT ) ("IsoTis"), an orthobiologics company, today ... it called to approve,the acquisition of IsoTis by Integra ... an agreement and plan of merger,dated as of August ... held at 9 a.m. Pacific time,today. An insufficient number ...

... Oct. 11 CV Therapeutics,Inc. (Nasdaq: CVTX ) ... for 2007 after the market closes on Tuesday, November ... 4:30 p.m. EST,1:30 p.m. PST, on the company,s website. ... to the Company,s website at, http://www.cvt.com and go ...

... to be initiated by end of 2007 -, ... BIIB ) and PDL BioPharma, Inc. (PDL) (Nasdaq: ... a significant reduction in new or,enlarged gadolinium-enhancing lesions when ... active relapsing multiple,sclerosis (MS). These data will be presented ...

Cached Biology Technology:IsoTis Adjourns Special Meeting to October 23, 2007 2 IsoTis Adjourns Special Meeting to October 23, 2007 3 IsoTis Adjourns Special Meeting to October 23, 2007 4 CV Therapeutics To Announce 2007 Third Quarter Financial Results on Tuesday, November 6, 2007 2 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 2 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 3 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 4 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 5 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 6

IsoTis Adjourns Special Meeting to October 23, 2007 CV Therapeutics To Announce 2007 Third Quarter Financial Results on Tuesday, November 6, 2007 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy

(Date:6/18/2013)... , June 19, 2013 Paris Air Show ... Geotest-Marvin Test Systems) , a leading provider of ... industries, is demonstrating its solutions this week at ... 3-C82. With growing challenges including increasingly complex armament ... efficient, feature-rich, specialized aerospace test solutions that address ...

(Date:6/18/2013)... at the University of Calgary,s Faculty of Medicine have ... body from harmful bacteria. Platelets, a component of blood ... for specific bacteria, and upon detection, seal it off ... were published in Nature Immunology this week, ... immunity. , "The science community has known that platelets ...

(Date:6/18/2013)... Researchers from the United Kingdom, the Energy Department,s ... of Kentucky have recently published a paper describing ... borer Limnoria quadripunctata , commonly known as ... because they exhibit a relatively unique ability to ... microbes to break down the biomass they eat. ...

Breaking Biology News(10 mins):Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 2 Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 3 Immunity mechanism discovered 2 Novel enzyme from tiny gribble could prove a boon for biofuels research 2

[0] Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show [0] Immunity mechanism discovered [0] Novel enzyme from tiny gribble could prove a boon for biofuels research

... the growing demand from the public and the scientific ... Press has revised its copyright policy to allow authors ... three journals. The policy, which became effective May 1, ... Journal of Cell Biology, The Journal of Experimental Medicine ...

... the human genome has been sequenced, research into mechanism of ... most human genes have not been isolated. This is true ... protein kinases, which mediate the majority of signaling events in ... It has been estimated by systematic gene sequencing efforts that ...

... which he calls a "smarthroscope", may be able to ... could be useful in developing countries. It aims ... the tissue surrounding an area affected by illnesses such ... and bone damage. The instrument would also help ...

Cached Biology News:Rockefeller University Press allows authors to retain copyright to their published work 2 QUT researchers develop smart instrument for tissue damage assessment 2

Rockefeller University Press allows authors to retain copyright to their published work Researchers report the cloning of a key group of human genes, the protein kinases QUT researchers develop smart instrument for tissue damage assessment

... extends the legendary MSn performance of the ... information through Thermo Scientifics innovations in ion ... is the only mass spectrometer that offers ... Pulsed Q Collision Induced Dissociation (PQD) ...

... The reliable and compact GC-8A is ... applications. Economical and simple to use, the ... or flow control, on column injection port(s), ... ramp program models are available. The GC-8A ...

... system combines world-class performance hardware, Cerity Networked ... world-renowned support and columns, as well as ... that lets you reach uncompromising results and ... data. The Agilent 6820 GC system is ...

... new chapter to a 40-year ... 7890A GC gives you everything ... lab to the next level ... including advanced separation capabilities, powerful ...

Biology Products:

LTQ XL with ETD from Thermo Scientific GC-8 Gas Chromatograph from Shimadzu 6820 GC from Agilent Technologies 7890A GC from Agilent Technologies